ArticleScientific reports2025
Study of the efficacy and the mechanism of action of lanreotide for the treatment of persistent diabetic macular edema.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions.International journal of molecular sciences · 2026Review
- Hormonal metabolic burden in diabetic retinopathy: the diabetic retina as an endocrine-responsive target organ.Frontiers in endocrinology · 2026Review
- The Long-Standing Problem of Proliferative Retinopathies: Current Understanding and Critical Cues.Cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The current treatments for diabetic macular edema (DME) include laser, steroids or vascular endothelial growth factors inhibitors (antiVEGF). Some DME are resistant to these treatments, which can respond to somatostatin inhibitors such as lanreotide. These drugs appear to influence the development of diabetic retinopathy (DR) and DME either through a direct antiVEGF effect or through the inhibition of growth hormone (GH), endothelial cell apoptosis and anti-inflammatory effect. It was conducted a study of the effects of lanreotide in retinal pigment epithelial cell cultures and a clinical study in patients with DME resistant to conventional treatments in order to better understand the usefulness of this drug. Lanreotide showed antiapoptotic effects and significantly improved visual acuity. Lanreotide could be applied in non-respondent patients to other treatments as an alternative in refractory DME patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.